B of A Securities Initiates Coverage On Viridian Therapeutics with Buy Rating, Announces Price Target of $47

Benzinga · 2d ago
B of A Securities analyst Daniel Giraldo initiates coverage on Viridian Therapeutics (NASDAQ:VRDN) with a Buy rating and announces Price Target of $47.